INTERNATIONAL SOCIETY FOR CNS DRUG DEVELOPMENT (EIN 030457495) - Form 990 Financial Analysis & Trantor Score

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2002

Legal Domicile

Phone

8588882934

Tax Period

2025-01-01 to 2025-12-31

INTERNATIONAL SOCIETY FOR CNS DRUG DEVELOPMENT, founded in 2002, is a small nonprofit in the Science & Technology sector that reported $597K in total revenue in fiscal year 2025. Revenue surged 79% from the prior year, signaling strong growth momentum. The organization ran a surplus of $106K, a strong 18% operating margin.

Mission

To focus on addressing scientific challenges in CNS drug development, through research and collaboration among stakeholders including academia, industry and government.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2025)

Revenue Breakdown

Contributions & Grants $418,651

Program Service Revenue $193,840

Investment Income $-15,197

Other Revenue $0

TOTAL REVENUE $597,294

Expense Breakdown

Grants Paid $0

Salaries & Benefits $315,695

Fundraising Expenses $96,799

Program Expenses $201,269

Other Expenses $175,978

TOTAL EXPENSES $491,673

Year-over-Year Comparison

	2025	2024	Change
Revenue	$597,294	$332,821	+0.8%
Expenses	$491,673	$340,184	+0.4%
Net Income	$105,621	$-7,363	-15.3%

Key Indicators

✗ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

N/A

Employees

Volunteers

N/A

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

$260,138

Total Directors

$260,138

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
AMIR KALALI	CFO/SECRETARY	20.00	Officer Director	$260,138	$0	$260,138
BILL MARTIN	Chairman	1.00	Director	$0	$0	$0
DAVID DANIEL	Director	1.00	Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2025	$597,294	$491,673	$2,110,811	$105,621
2024	$332,093	$340,184	$713,627	$-8,091
2024	$332,821	$340,184	$713,627	$-7,363
2023	$337,601	$366,257	$702,422	$-28,656
2022	$264,738	$324,620	$732,271	$-59,882
2021	$237,467	$218,115	$789,786	$19,352
2020	$316,917	$161,254	$808,207	$155,663
2019	$270,813	$189,336	$616,668	$81,477
2018	$223,262	$197,375	$543,413	$25,887

INTERNATIONAL SOCIETY FOR CNS DRUG DEVELOPMENT